Dr. John Cush RheumNow
2 years 9 months ago
You can still attend RheumNow Live!
This 1.5-day long meeting offers pre-learning modules, shorter, concise lectures with clinical context and audience input, more discussion time, and sessions that are relaxed and comprehensive.
Register: https://t.co/iWiFunwbNH https://t.co/3HmR7qqTMT
SPACE study of adults referred to rheumatology with less than 2 years of chronic back pain (CBP), shows that only one-third can be reliably diagnosed with axial spondyloarthritis (axSpA).
Dr. John Cush RheumNow
2 years 9 months ago
Data from the American Rheumatology Network (2014–2021) shows that among 15182 new TNFi initiations, only 45% had a dz activity measure (CDAI/RAPID3); and of these, only 47% had a TJC, SJC or pain score. Can you treat HTN without measuring BP? https://t.co/SsnF7Taky1 https://t.co/LN72IAWs8n
Dr. John Cush RheumNow
2 years 9 months ago
Tic-Borne Disorders Causing Chronic Arthritis?
Findings from a population based cross-sectional study suggests that while up to 20% of patients have antibodies to tick-borne exposures, only a minority reported musculoskeletal symptoms.
https://t.co/FWhCl3v8oH https://t.co/NDgvKYva11
The original randomized controlled, prospective MAINRITSAN study of 115 patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis [AAV]) demonstrated superiority of rituximab (RTX) over azathioprine (AZA) for maintenance of remission at 22 months in ANCA-associated vasculitis patients after CYC remission induction.
Dr. John Cush RheumNow
2 years 9 months ago
New download available!
Seasonal Flu Vaccination in RA Patients
https://t.co/pLz8yo28QM https://t.co/7rKymy79jI
Dr. John Cush RheumNow
2 years 9 months ago
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/2qX1F6ZP6J https://t.co/zoknjDgMQy
Dr. John Cush RheumNow
2 years 9 months ago
QD Clinic - Suspend MTX How Long?
Pregnancy and MTX - how long do you have to be off?
https://t.co/pTz8nlHpWN https://t.co/YrG7cKgbvF
Dr. John Cush RheumNow
2 years 9 months ago
QD Clinic - To Aspirate or Not
RA patient in need to an injection; do you aspirate first?
https://t.co/lOA5glSmfs https://t.co/FUvBFa8H7Q
Mike Putman EBRheum
2 years 9 months ago
Excited to be talking at https://t.co/hposbnLVdD!!
As usual, @RheumNow screen-grabbed me at an opportune moment 🤣😆
Highly recommend the conference; register live/online at the link above! https://t.co/XewJXRASi8
Dr. John Cush RheumNow
2 years 9 months ago
2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).
https://t.co/B7hE9jaGuo https://t.co/WCZ0VNcdKR
Dr. John Cush RheumNow
2 years 9 months ago
Mayo study shows multimorbidity in RA increases serious infx (SI) risk; 911 RA pts (56 yrs, 2/3 seropositive) 17% had SI (3.9/100PY). Hi risk morbidities(bipolar Dz, CKD, COPD,, chr skin ulcers) were assoc w/ 3 to 5-fold increased SI risk https://t.co/qorKp96KTm https://t.co/o5FaMKMskA
Dr. John Cush RheumNow
2 years 9 months ago
Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had more postoperative flares (29% v 12%, P=.01), esp if JAKi held >11d (p.04). No diff in other postop complications https://t.co/E2fJS3N7KU https://t.co/4H00TgXVr2
